SCYNEXIS, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- $56M
- Website
- http://www.scynexis.com
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary
FDA accepts GSK's NDA for gepotidacin, a novel oral antibiotic for uUTIs, with a PDUFA action date of 26 March 2025. Gepotidacin, supported by positive EAGLE-2 and EAGLE-3 trials, could be the first new class of oral antibiotic for uUTIs in over 20 years.
© Copyright 2024. All Rights Reserved by MedPath